Randomized trial · people

CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3

Checked against the paper Randomized trialPublished by PepVault

The takeaway

For people with type 2 diabetes on basal insulin, adding weekly CagriSema at either tested dose lowered HbA1c clearly more than placebo and came with weight loss, with no severe low blood sugar seen in this trial.

Kind
Randomized trial
Studied in
People
Number studied
274
Published
2026
Journal
Lancet

What they tested

The team tested whether weekly CagriSema (cagrilintide plus semaglutide) works better than placebo at controlling blood sugar in adults with type 2 diabetes already on daily basal insulin, and whether it is safe.

How the study was done

A randomized, double-blind, placebo-controlled phase 3 trial at 46 centers in six countries, in 274 adults with type 2 diabetes and HbA1c (a 3-month average of blood sugar) of 7.0-10.5% who were on stable once-daily basal insulin, with or without metformin. For 40 weeks they got a weekly shot under the skin of cagrilintide 2.4 mg plus semaglutide 2.4 mg, cagrilintide 1.0 mg plus semaglutide 1.0 mg, or a matching placebo (a dummy shot).

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking CagriSema? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 40, HbA1c fell by 2.33% in the 2.4 mg arm and 2.10% in the 1.0 mg arm, against 0.66% on placebo. Compared with placebo, the treatment difference was -1.68 percentage points for the 2.4 mg arm and -1.44 percentage points for the 1.0 mg arm (both p<0.0001). Body weight dropped by 10-12% on CagriSema. Side effects were reported by 80% of the 2.4 mg arm, 71% of the 1.0 mg arm and 71% on placebo, mostly mild or moderate stomach and gut problems, and no one had severe hypoglycemia (dangerously low blood sugar).

What it doesn’t show

The trial ran 40 weeks in 274 people, so it cannot show long-term effects, and it only included adults already on stable basal insulin within a set HbA1c range. It was funded by Novo Nordisk.

The paper

Rosenstock et al. Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. Lancet. 2026.

The compounds

More studies on CagriSema

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking CagriSema? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo